44-Gene Assay Predicts Response, Survival in Esophageal Cancer (CME/CE)
(MedPage Today) -- DNA-damaging immune response in tumors correlates with neoadjuvant therapy efficacy, will aid personalized treatment
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news
More News: Cancer | Cancer & Oncology | Esophagus Cancer | Gastroenterology | Genetics | Neoadjuvant Therapy